Neuropeptide S (NPS) increases wakefulness. A small number of neurons in the brainstem express Nps. These neurons are located in or near the parabrachial nucleus (PB), but we know very little about their ontogeny, connectivity, and function. To identify Nps-expressing neurons within the molecular framework of the PB region, we used in situ hybridization, immunofluorescence, and Cre-reporter labeling in mice.The primary concentration of Nps-expressing neurons borders the lateral lemniscus at far-rostral levels of the lateral PB. Caudal to this main cluster, Nps-expressing neurons scatter through the PB and form a secondary concentration medial to the locus coeruleus (LC). Most Nps-expressing neurons in the PB region are Atoh1-derived, Foxp2-expressing, and mutually exclusive with neurons expressing Calca or Lmx1b.Among Foxp2-expressing PB neurons, those expressing Nps are distinct from intermingled subsets expressing Cck or Pdyn. Examining Nps Cre-reporter expression throughout the brain identified novel populations of neurons in the nucleus incertus, anterior hypothalamus, and lateral habenula. This information will help focus experimental questions about the connectivity and function of NPS neurons.
INTRODUCTIONWake-promoting stimulants like caffeine and amphetamines are inherently anxiogenic. Despite the benefits of enhanced wakefulness and attention, their anxiogenic propensity limits therapeutic potential in patients with inattention or hypersomnolence. Conversely, sedative effects of most anxiolytic drugs limit their use in patients with insomnia or anxiety. These complementary limitations frustrate the treatment of many patients with cognitive, affective, and sleep disorders. A nonanxiogenic stimulant medication or nonsedative anxiolytic medication would be enormously beneficial. For these reasons, the discovery of neuropeptide S (NPS) was an exciting development. NPS was identified Dake Huang and Richie Zhang contributed equally.